These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30670411)

  • 21. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
    Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
    Ruiz VH; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
    Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(3):1671-7. PubMed ID: 24379195
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
    Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
    [No Abstract]   [Full Text] [Related]  

  • 26. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
    Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.
    Everett M; Sprynski N; Coelho A; Castandet J; Bayet M; Bougnon J; Lozano C; Davies DT; Leiris S; Zalacain M; Morrissey I; Magnet S; Holden K; Warn P; De Luca F; Docquier JD; Lemonnier M
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
    Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
    J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.
    Wachino JI; Jin W; Kimura K; Kurosaki H; Sato A; Arakawa Y
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184250
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
    Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.
    van der Zwaluw K; Witteveen S; Wielders L; van Santen M; Landman F; de Haan A; Schouls LM; Bosch T;
    Clin Microbiol Infect; 2020 Oct; 26(10):1412.e7-1412.e12. PubMed ID: 32006688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.